Blte.O
BLTE.O is a biotechnology company focused on the development of novel therapeutics for the treatment of cancer, leveraging its proprietary platform to discover and develop small molecule drugs.
Business. BLTE.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BLTE.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
BLTE.O maintains a strong liquidity position, with a current ratio of 50.02, indicating that its current assets significantly exceed its current liabilities. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure with no leverage. However, the company reported negative operating and free cash flows of -$36.99 million and -$77.50 million, respectively, indicating ongoing cash burn.
Profitability metrics show BLTE.O is currently unprofitable, with a net loss of -$77.61 million and a return on equity (ROE) of -10.07%. These figures are below the industry median for ROE, which is typically positive for biotechnology firms with successful drug candidates in late-stage development. The company's return on assets (ROA) of -9.94% further underscores the lack of asset efficiency in generating returns.
BLTE.O operates as a single-segment company, with all revenue derived from its biotechnology platform and drug development activities. The company does not disclose geographic revenue breakdowns, but its operations are primarily based in the United States. This lack of geographic diversification may expose the company to regulatory and market risks specific to the U.S. healthcare environment.
The company's growth trajectory is currently constrained by its negative operating income of -$84.21 million and a lack of disclosed revenue. While BLTE.O is in the early stages of clinical development, the absence of commercialized products means it is not yet generating revenue from product sales. The outlook for the next fiscal year remains uncertain, with no disclosed revenue growth or margin improvement expected in the near term.
Risk factors for BLTE.O include the high failure rate of drug candidates in clinical trials, regulatory hurdles, and the need for significant capital to advance its pipeline. The company has not issued any dilutive shares in the past 12 months, and there are no immediate filing-based dilution flags. However, the company may need to raise additional capital to fund operations, which could lead to future dilution.
Recent events include the company's continued focus on advancing its lead candidate, BL-8040, into Phase 2 clinical trials. No recent earnings calls or 10-K filings have been disclosed that would indicate a material change in strategy or financial position.
- BLTE.O is a pre-revenue biotechnology company with no long-term debt and a strong liquidity position.
- The company is currently unprofitable, with negative operating and free cash flows, and ROE and ROA below industry norms.
- BLTE.O operates as a single-segment company with no geographic diversification, exposing it to U.S.-centric regulatory and market risks.
- The company is in the early stages of clinical development and has not yet commercialized any products, limiting its revenue potential.
- BLTE.O faces high clinical and regulatory risks, and may need to raise additional capital in the future, which could lead to dilution.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Medical Officer · Stock Option (right to buy) → Ordinary SharesAcquired 10 000 @ $77,40other · 2026-04-21
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Return On Equitynet_income / total_equity
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- BLTE.O Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$123M
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$32M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$3M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Yu-Hsin LinChairman of the Board, Chief Executive Officer
Insider activity
- Chief Medical Officer · American depositary shareSold 96 @ $143,90$14K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 3 748 @ $144,66$542K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 4 861 @ $145,43$707K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 1 199 @ $146,24$175K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 96 @ $147,11$14K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 540 @ $140,58$76K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 2 054 @ $137,61$283K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 784 @ $138,18$108K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 3 140 @ $139,57$438K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 100 @ $141,83$14K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 450 @ $142,20$64K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 1 897 @ $143,55$272K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 1 035 @ $145,02$150K · 2026-06-16
- Chief Scientific Officer · American depositary shareSold 9 @ $155,25$1K · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 428 @ $153,56$66K · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 3 @ $154,61$464 · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 226 @ $152,45$34K · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 240 @ $154,41$37K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 100 @ $155,97$16K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 424 @ $152,67$65K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 8 @ $151,57$1K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 100 @ $156,00$16K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 128 @ $153,42$20K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 121 @ $156,53$19K · 2026-05-05
- Chief Scientific Officer · American depositary shareSold 120 @ $153,92$18K · 2026-05-05
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -26.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -95.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -114.7%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -38.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -95.8%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 1,014.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 59.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 413.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 428.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 51.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -110.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -10.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -9.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 50.02xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.01xDerived (calculated)
- Pre-tax income (annual): USD -77.61MSEC XBRL filing
- Total operating expenses (annual): USD 84.21MSEC XBRL filing
- Capex (annual): USD 71KSEC XBRL filing
- Cash & equivalents (annual): USD 352.93MSEC XBRL filing
- Current liabilities (annual): USD 9.88MSEC XBRL filing
- Current assets (annual): USD 494.27MSEC XBRL filing
- Shareholders' equity (annual): USD 770.49MSEC XBRL filing
- Shares outstanding (annual): 39.34MSEC XBRL filing
- Total liabilities (annual): USD 10.07MSEC XBRL filing